ReviewDrug design, development and therapy2026

Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential Therapy.

Ahmad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.